Edward M. Kaye MD - 03 Dec 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Reporting relationship: Director
Issuer ticker: STOK
Reported as of: 03 Dec 2025
Net transaction value: -$466,959
SEC form: 4
Accepted by SEC: 05 Dec 2025, 20:50:19 UTC
Prior SEC filing: 03 Dec 2025
Next SEC filing: 10 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Allan, Attorney-in-Fact

Key filing fact

Edward M. Kaye MD filed Form 4 for Stoke Therapeutics, Inc. (STOK) on 05 Dec 2025.

Key facts

This page summarizes Edward M. Kaye MD's Form 4 filing for Stoke Therapeutics, Inc. (STOK).
7 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Dec 2025, 20:50.

Change

Previous filing in this sequence was filed on 03 Dec 2025.
Current net transaction value: -$466,959.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001522780 Primary reporting owner

Kaye Edward M. MD

Relationship: Director
Address: C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD
Signature: /s/ Jonathan Allan, Attorney-in-Fact
Signature date: 05 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

STOK transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +26,250
Change %: +51%
Price: $0.000000
Shares after: 77,555
Date: 03 Dec 2025
Ownership: Direct

STOK transaction

Common Stock

Sale

Transaction value: $160,647
Shares: -5,222
Change %: -6.7%
Price: $30.76
Shares after: 72,333
Date: 04 Dec 2025
Ownership: Direct
Footnotes: F1, F2

STOK transaction

Common Stock

Sale

Transaction value: $38,550
Shares: -1,231
Change %: -1.7%
Price: $31.32
Shares after: 71,102
Date: 04 Dec 2025
Ownership: Direct
Footnotes: F1, F3

STOK transaction

Common Stock

Sale

Transaction value: $199,481
Shares: -6,367
Change %: -9%
Price: $31.33
Shares after: 64,735
Date: 05 Dec 2025
Ownership: Direct
Footnotes: F1, F4

STOK transaction

Common Stock

Sale

Transaction value: $52,358
Shares: -1,681
Change %: -2.6%
Price: $31.15
Shares after: 63,054
Date: 05 Dec 2025
Ownership: Direct
Footnotes: F5, F6

STOK transaction

Common Stock

Sale

Transaction value: $15,923
Shares: -500
Change %: -0.79%
Price: $31.85
Shares after: 62,554
Date: 05 Dec 2025
Ownership: Direct
Footnotes: F5, F7

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STOK transaction Derivative

Performance Stock Units

Options Exercise

Transaction value: $0
Shares: -26,250
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 03 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,250
Exercise price
Footnotes: F8, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 9 footnotes

Footnote F1

The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

Footnote F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4.

Footnote F3

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive.

Footnote F5

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

Footnote F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.69 to $31.61 per share, inclusive.

Footnote F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 to $31.96 per share, inclusive.

Footnote F8

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

Footnote F9

Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.